Comparing Low-Intensity and Medium-Intensity Continuous Kidney Replacement Therapy in Critically Ill Adults
Led by Jikei University School of Medicine · Updated on 2026-08-05
400
Participants Needed
9
Research Sites
39 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating whether low treatment intensity 12 mLkghr or medium treatment intensity 25 mLkghr continuous kidney replacement therapy is more effective and safer for critically ill patients with acute kidney injury. This interventional clinical trial is sponsored by Jikei University School of Medicine and uses a randomized, parallel study design to compare these two dosing strategies in an intensive care setting. The study is conducted to understand the best approach to continuous renal replacement therapy for patients requiring this treatment.
Participants are randomly assigned to receive either low-intensity or medium-intensity continuous hemodialysis andor hemofiltration, delivered through dialysate fluid and filtration replacement fluid. The study compares these two dosing levels, with interventions administered continuously while patients are in intensive care units. The trial includes phases 2 and 3 and is planned to complete by June 2030.
During the study, participants are monitored for outcomes such as death and duration of kidney replacement therapy over 28 days or until hospital discharge, whichever comes first. Additional evaluations include ICU and hospital mortality, dialysis dependence, vasopressor-free days, ventilator-free days, serum creatinine levels, and urine output at kidney replacement therapy end. The total participation timeline extends up to hospital discharge or 90 days, with assessments performed at multiple time points to measure treatment effects and safety.
CONDITIONS
Brief Title
Low-intensity Versus Medium-intensity Continuous Kidney Replacement Therapy for Critically Ill Patients
Research Team
T
Tomoko Fujii, MD,PhD
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match. Sign up to get personalized trial recommendations delivered to your inbox.
Adults 18 years of age or older admitted to an intensive care or high care unit
Diagnosis of acute kidney injury by KDIGO criteria with recent serum creatinine increase or oliguria
Treating intensivist believes continuous kidney replacement therapy is necessary
Informed consent given by patient or substitute decision maker
You will not qualify if you...
Receiving chronic dialysis or scheduled to start chronic dialysis
Having undergone any kidney replacement or blood purification therapy within 48 hours
Preference for other dialysate or replacement fluids due to bleeding disorders or acetate allergy
Receiving blood purification therapies other than hemofiltration or dialysis, such as plasma exchange
Very critical condition with expected survival less than 24 hours
Previous participation in this study
Lack of consent to participate
Investigator's judgment of inappropriate participation
Your Study Journey
Screening
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Treatment
Duration - Up to 28 days or until hospital discharge
Participants receive continuous kidney replacement therapy at either low or medium treatment intensity as assigned by randomization.
Regular monitoring during ICU stay
Follow-up
Duration - Up to 90 days or until hospital discharge
Participants are monitored for outcomes such as death, kidney therapy duration, dialysis dependence, and organ function up to 90 days or hospital discharge.
Periodic assessments during hospital stay
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Published Research Related To This Trial
Proceedings of the University of Alabama at Birmingham Continuous Renal Replacement Therapy Academy (2023-2024): Managing De-Escalation of Acute Renal Replacement Therapy and Optimizing Drug Dosing during Renal Replacement Therapy Transitions.
William Beaubien-Souligny, Melissa Thompson Bastin, J Pedro Teixeira...